A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price increase of 43.64%. However, over the past six months, we’ve seen a weaker performance of 23.63%. The price of TSHA leaped by -15.19% over the last 30 days. And in the last five days, it has fallen by -6.23%.
Taysha Gene Therapies Inc experienced a rather shaky stock market performance.
52-week price history of TSHA Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Taysha Gene Therapies Inc’s current trading price is -24.92% away from its 52-week high, while its distance from the 52-week low is 136.67%. The stock’s price range during this time has been between $1.05 and $3.31. The trading volume for the Healthcare sector company’s shares reached about 3.67 million for the day, which was lower than the average daily volume of 3.68 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Taysha Gene Therapies Inc (TSHA) has experienced a quarterly rise of 46.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 649.90M and boasts a workforce of 73 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
TSHA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TSHA stands at 1.13. Similarly, the long-term debt-to-equity ratio is also 1.09.
